3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Thrombocytopenia
14
Leukemia, Myeloid, Acute
11
Leukemia
7
Myelodysplastic Syndromes
5
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Lymphocytic, Chronic, B-Cell
3
Jacobs syndrome
3
Sarcoma
2
Purpura, Thrombocytopenic, Idiopathic
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Hematologic Neoplasms
2
Congenital Abnormalities
2
Solid Tumor, Childhood
1
Recurrence
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Rosuvastatin Calcium
2
technetium 99m HYNIC-duramycin
1
eltrombopag
1
darolutamide
1
Magnetic Iron Oxide Nanoparticles
1
Gelatin
1
Decision Support Techniques
1
Contrast Media
1
Cell Death
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Healthy Volunteers
×
eltrombopag
×
Clear all
NCT04542382
2025-03-30
BCRPmarker
University of California, San Francisco
Phase 1
Completed
11 enrolled